Available clinical trials

Brain

  • 14058: Ph II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Vs Conventional Photon Irradiation with Concomitant and Adj Temozolomide in Pts w/ Newly Diagnosed Glioblastoma
    Click here for more information

Breast

  • 17082: (I3Y-MC-JPCF)A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
    Click here for more information
  • 16218: POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
    Click here for more information
  • 13091: A Randomized Phase III Clinical Trial Evaluating Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
    Click here for more information

Esophageal

  • 16165: CA209648: A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma(CheckMate 648: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 648)
    Click here for more information

Gastric

  • 16164: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab Clinical Trial Evaluation 649)
    Click here for more information

Head & Neck

  • 16204: A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412)
    Click here for more information
  • 10025: A phase III study of postoperative radiation therapy (IMRT) +/- cetuximab for locally-advanced resected head and neck cancer (RTOG 0920)
    Click here for more information

Hematologic and Leukemia

  • 15229: (UTX-TGR-304) Ph 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Comb. with TGR-1202 Compared to Obinutuzumab in Comb. with Chlorambucil in Patients with CLL
    Click here for more information
  • 15005: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M)
    Click here for more information

Lung

  • 16156: CA209-817: A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
    Click here for more information

Lymphoma

  • 17093: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205
    Click here for more information
  • 17050: (GO39942): A PHASE III, MULTICENTER, RANDOMIZED,DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
    Click here for more information
  • 17041: Screening Protocol: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma
    Click here for more information
  • 16100: Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices (CA209655)
    Click here for more information
  • 15223: A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204)
    Click here for more information
  • 13092: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)
    Click here for more information
  • 13064: Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or MCL (CC-5013-NHL-008)
    Click here for more information
  • 11282: A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
    Click here for more information

Myelofibrosis

  • 17085: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
    Click here for more information

Myelomas

  • 17081: C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen
    Click here for more information

Ovarian

  • 16233: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523
    Click here for more information
  • 16211: PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA)
    Click here for more information
  • 16080: A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMB. WITH AND/OR FOLLOWING CHEMO IN PTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER (B9991010)
    Click here for more information

Prostate

  • 16159: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESISINHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN - Roche CO39385

    Click here for more information

Renal Cell

  • 17103: A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
    Click here for more information

Solid Tumors

  • 16154: Non-interventional, research evaluation of functional T-cell responses to tumor-associated mutations identified among solid tumors by ATLAS™ (ATL-009-S01)
    Click here for more information
  • 16041: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
    Click here for more information
  • 15026: Efficacy and Safety of Rivaroxaban Prophylaxis Compared w/ Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)
    Click here for more information

Urothelial

  • 16054: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemo vs Chemo in Subjects with Adv. or Metastatic Urothelial CA (MK-3475-361)
    Click here for more information
  • 15228: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)
    Click here for more information